5-(tryptophylamino)-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-based cholecystokinin receptor antagonists: reversal of CCK1 receptor subtype selectivity toward CCK2 receptors.
Muñoz-Ruiz
Pilar
P
Instituto de Química Médica (CSIC), Juan de la Cierva 3, E-28006 Madrid, Spain.
García-López
M Teresa
MT
Cenarruzabeitia
Edurne
E
Del Río
Joaquín
J
Dufresne
Marlene
M
Foucaud
Magali
M
Fourmy
Daniel
D
Herranz
Rosario
R
D000681:Amylases / Q000378:metabolism; D000818:Animals; D001667:Binding, Competitive; D019556:COS Cells; D002540:Cerebral Cortex / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D066298:In Vitro Techniques; D010179:Pancreas / Q000187:drug effects / Q000378:metabolism; D011725:Pyridines / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D011743:Pyrimidines / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D011869:Radioligand Assay; D051381:Rats; D043887:Receptor, Cholecystokinin B / Q000037:antagonists & inhibitors*; D054389:Receptors, CCR1; D019707:Receptors, Chemokine / Q000037:antagonists & inhibitors*; D013237:Stereoisomerism; D013329:Structure-Activity Relationship
C515300:CCR1 protein, human; C515302:Ccr1 protein, rat; D011725:Pyridines; D011743:Pyrimidines; D043887:Receptor, Cholecystokinin B; D054389:Receptors, CCR1; D019707:Receptors, Chemokine; D000681:Amylases